Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Hyperimmune Globulins Market Size Forecast: How Big Could The Market Get By 2030?
The hyperimmune globulins market size has shown significant growth in recent years. It is projected to expand from $2.06 billion in 2025 to $2.21 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.6%. The expansion witnessed in the past can be attributed to its established application in rabies and tetanus prophylaxis, the rising occurrence of infectious diseases, the reliance on plasma-derived therapies, various government immunization programs, and the increasing availability of hospital-based emergency care.
The hyperimmune globulins market is projected to experience substantial expansion in the coming years, reaching an estimated $2.86 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.7%. This anticipated growth is primarily attributable to factors such as a rise in organ transplantation rates, an increase in viral infection outbreaks, the ongoing expansion of plasma donation infrastructure, continuous advancements in purification technologies, and a heightened focus on achieving rapid immune protection. Concurrently, significant trends expected during this forecast period include an escalating demand for passive immunization therapies, a wider application in post-exposure prophylaxis, greater adoption in transplant and immunocompromised patient care, the scaling up of plasma collection and fractionation capacity, and a reinforcement of regulatory oversight and quality standards.
Get A Free Sample Report With In-Depth Market Insights:
Hyperimmune Globulins Market Demand Drivers: What’s Powering Industry Growth?
The growing occurrence of infectious diseases is projected to stimulate the expansion of the hyperimmune globulin market in the future. Infectious diseases are illnesses resulting from harmful agents (pathogens) like viruses, bacteria, fungi, and parasites entering the body. The rise in these diseases can be linked to factors such as antimicrobial resistance, climate change, and population growth. Hyperimmune globulins are employed in cases of infectious diseases to confer immediate passive immunity, providing concentrated antibodies against specific pathogens, thereby aiding in the prevention or treatment of conditions such as rabies, hepatitis B, or tetanus. For example, in August 2024, a report by the UK Health Security Agency, a UK-based government agency, indicated that in 2023, the West Midlands region reported the highest number of measles cases, with 160 cases (44%), followed by London with 122 cases (33%). Significantly, children under the age of 10 accounted for 63% of all cases, totaling 232 cases. Measles activity experienced a considerable surge towards the year’s end, with 157 new cases documented in December, contrasting with just 45 cases in November. Consequently, the increasing prevalence of infectious diseases is fueling the growth of the hyperimmune globulin market. Government-led initiatives for research and development within the healthcare sector are anticipated to foster the growth of the hyperimmune globulins market moving forward. The increase in these governmental R&D efforts stems from a heightened demand for innovative medical solutions and the necessity to address new health challenges. Such initiatives facilitate the development and availability of hyperimmune globulins for effectively combating specific infectious diseases. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure witnessed a 5.6% increase in nominal terms from 2022 to 2023, signifying a notable acceleration compared to the 0.9% growth recorded in 2022. Thus, the escalating government initiatives for healthcare research and development are propelling the hyperimmune globulins market.
Hyperimmune Globulins Market Segment Analysis: What Are The Core Market Categories?
The hyperimmune globulins market covered in this report is segmented –
1) By Type: Hepatitis B Hyperimmune Globulin, Rabies Hyperimmune Globulin, Tetanus Hyperimmune Globulin, Cytomegalovirus (CMV) Hyperimmune Globulin, Varicella-Zoster Virus (VZV) Hyperimmune Globulin, Respiratory Syncytial Virus (RSV) Hyperimmune Globulin, Other Types
2) By Route Of Administration: Intramuscular, Intravenous
3) By Application: Government Institution, Private Sector, Other Applications
Subsegments:
1) By Hepatitis B Hyperimmune Globulin: Intramuscular Hepatitis B Hyperimmune Globulin, Intravenous Hepatitis B Hyperimmune Globulin
2) By Rabies Hyperimmune Globulin: Rabies Immune Globulin (Human), Rabies Immune Globulin (Equine)
3) By Tetanus Hyperimmune Globulin: Tetanus Immune Globulin (Human), Tetanus Immune Globulin (Equine)
4) By Cytomegalovirus (Cmv) Hyperimmune Globulin: Cmv Immune Globulin For Organ Transplantation, Cmv Immune Globulin For Neonatal Infection
5) By Varicella-Zoster Virus (Vzv) Hyperimmune Globulin: Vzv Immune Globulin For Post-Exposure Prophylaxis, Vzv Immune Globulin For Immunocompromised Patients
6) By Respiratory Syncytial Virus (Rsv) Hyperimmune Globulin: Rsv Immune Globulin For Infants And Children, Rsv Immune Globulin For Adults With Respiratory Conditions
7) By Other Types: Diphtheria Hyperimmune Globulin, Botulism Hyperimmune Globulin, Other Specialized Hyperimmune Globulins
Hyperimmune Globulins Market Top Companies Driving Competitive Growth
Major companies operating in the hyperimmune globulins market are Bayer AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Ltd., Fresenius Kabi AG, Grifols SA, Octapharma AG, Shanghai RAAS Blood Products Co. Ltd., Emergent BioSolutions Inc., Kedrion Biopharma Inc., LFB SA, Hualan Biological Engineering Inc., Taibang Biologic Group, Bio Products Laboratory (BPL) Ltd., ADMA Biologics, Cangene Corporation, Kamada Ltd., Saol Therapeutics Inc., Shire, Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd.
View The Full Hyperimmune Globulins Market Report:
Hyperimmune Globulins Market Geographic Spread And Regional Opportunities
North America was the largest region in the hyperimmune globulins market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hyperimmune globulins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
